

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10634114
	Filing Date		2003-08-04
	First Named Inventor	Gary D. Glick	
	Art Unit	1618	
	Examiner Name	Ebrahim, Nabila G.	
	Attorney Docket Number	UM-08192	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	4551480		1985-11-05	Stiefel Werner K.		
	2	5141930		1992-08-25	Nakao		
	3	5444092		1995-08-22	Collins		
	4	5559230		1996-09-24	Ogawa		
	5	5591227		1997-01-07	Dihn		
	6	5599352		1997-02-04	Dihn		
	7	5697967		1997-12-16	Dihn		
	8	6074859		2000-06-13	Hirokawa		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim, Nabila G.
Attorney Docket Number	UM-08192

9	6524623		2003-02-25	Hodosh	
10	6524832		2003-02-25	Kufe	
11	7125866		2006-10-24	Glick	
12	7144880		2006-12-05	Glick	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040009972		2004-01-15	Ding	
	2	20040087489		2004-05-06	Ruiz	
	3	20040176358		2004-09-09	Glick	
	4	20050113460		2005-05-26	Glick	
	5	20050261176		2005-11-24	Glick	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim, Nabila G.
Attorney Docket Number	UM-08192

6	20030119029		2003-06-26	Glick	
7	20050272723		2005-12-08	Glick	
8	20060025388		2006-02-02	Glick	
9	20060052369		2006-03-09	Glick	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1398033	EP		2004-03-17	University Michigan US		<input type="checkbox"/>
	2	0227539	EP		1990-05-23	Clemence		<input type="checkbox"/>
	3	00/66106	WO		2000-11-09	Glick		<input type="checkbox"/>
	4	02/67988	WO		2002-09-06	The Regents of the University of Michigan		<input type="checkbox"/>
	5	05/004988	WO		2005-01-20	Glick		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim, Nabila G.
Attorney Docket Number	UM-08192

6	90/13332	WO		1990-11-15	Siegel		<input type="checkbox"/>
7	91/12779	WO		1991-09-05	Wolff		<input type="checkbox"/>
8	94/08234	WO		1994-04-14	Labintelligence Inc.		<input type="checkbox"/>
9	98/57161	WO		1998-12-17	Hoefer Pharmacia Biotech		<input type="checkbox"/>
10	92/01683	WO		1992-02-06	Sato		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ATWAL, K.S., et al., "N-(1-Aryl-2-(1-imidazolo)ethyl)-guanine derivatives as potent inhibitors of the bovine mitochondrial F140 ATP hydrolase" Bioorganic & Medicinal Chem. Ltr., Vol. 14, pp. 1021-1030 (2004)	<input type="checkbox"/>
	2	BLATT, Neal B., "Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility", The Journal of Clinical Investigation, October 2002, vol. 110, no. 8., pp. 1123-1132	<input type="checkbox"/>
	3	BOITANO, Anthony, et al., "Structure activity studies of a novel cytotoxic benzodiazepine", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 13, no. 19, 2003, pp. 3327-3330.	<input type="checkbox"/>
	4	BONO et al., "Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities," Biochemical and Biophysical Research Communications, 1999, 265, pp. 457-461	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim, Nabila G.
Attorney Docket Number	UM-08192

5	BUNIN et al., "Synthesis and evaluation of 1,4-benzodiazepine libraries", Methods in Enzymology, 1996, 267, pp 448-465	<input type="checkbox"/>
6	DICHEK, David A., et al., "Seeding of intravascular stents with genetically engineered endothelial cells," Laboratory Investigation, 80:5 pp.1347-1353 (1999)	<input type="checkbox"/>
7	DON,A. et al., Cancer Cell, Vol. 3, May(2003) 497-509	<input type="checkbox"/>
8	GUPTA et al., "Psychitripic drugs in dermatology...." Database:EMbase (AN:86111413), Journal of the American Academy of Dermatology, 1986, Vol. 14, No. 4, pp. 633-645	<input type="checkbox"/>
9	KARLE JESPER et al., "Diazepam protects against rat hippocampal neuronal cell death induced by antisense oligodeoxynucleotide to GABA-A receptor gamma-2 subunit" Brain Research, vol. 765, no. 1, 1997, pp. 21-29.	<input type="checkbox"/>
10	LEWIS et al., "Editors' view: Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms", British Journal of Clinical Pharmacology, 2006, 62:1,pp. 1-4	<input type="checkbox"/>
11	MIERNIK et al., "The antimitotic activities of some benzodiazepines", Experientia, 1986, 42, pp. 956-958	<input type="checkbox"/>
12	Paola Costantini ET AL., "Mitochondrion as Novel Target of Anticancer Chemotherapy", JNCI Journal of the National Cancer Institute 2000 92(13): 1042-1053; doi:10. 1093/jnci/92. 13. 1042.	<input type="checkbox"/>
13	RAMDAS et al., "Benzodiazepine compounds as inhibitors of the Src protein tyrosine kinase ..." Archives of Biochemistry and Biophysics 368 (1999) 394-400	<input type="checkbox"/>
14	WALSER, et al., "Quinazolines and 1,4-benzodiazepines. LIX. Preparation of Pyrrolo[2,1-c]-1,4-benzodiazepin-2-ones", J. Org. Chem. 38:3502-3507 (1973)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim, Nabila G.
Attorney Docket Number	UM-08192

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.